ZA200006986B - A membrane or matrix for controlling the permeation rate of drugs. - Google Patents
A membrane or matrix for controlling the permeation rate of drugs. Download PDFInfo
- Publication number
- ZA200006986B ZA200006986B ZA200006986A ZA200006986A ZA200006986B ZA 200006986 B ZA200006986 B ZA 200006986B ZA 200006986 A ZA200006986 A ZA 200006986A ZA 200006986 A ZA200006986 A ZA 200006986A ZA 200006986 B ZA200006986 B ZA 200006986B
- Authority
- ZA
- South Africa
- Prior art keywords
- groups
- poly
- elastomer
- sir
- alkylene oxide
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title claims description 23
- 239000003814 drug Substances 0.000 title claims description 23
- 239000012528 membrane Substances 0.000 title description 40
- 239000011159 matrix material Substances 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims description 140
- 239000000806 elastomer Substances 0.000 claims description 112
- 229920001971 elastomer Polymers 0.000 claims description 110
- 125000000217 alkyl group Chemical group 0.000 claims description 76
- -1 polysiloxane units Polymers 0.000 claims description 65
- 239000003054 catalyst Substances 0.000 claims description 50
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 48
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 41
- 229920000642 polymer Polymers 0.000 claims description 33
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 31
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 31
- 239000000306 component Substances 0.000 claims description 29
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 239000000945 filler Substances 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 229920002554 vinyl polymer Polymers 0.000 claims description 22
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 20
- 229920001296 polysiloxane Polymers 0.000 claims description 20
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 16
- 101150065749 Churc1 gene Proteins 0.000 claims description 16
- 102100038239 Protein Churchill Human genes 0.000 claims description 16
- 229920001002 functional polymer Polymers 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 150000002431 hydrogen Chemical class 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 150000004678 hydrides Chemical class 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 150000002978 peroxides Chemical class 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 4
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 description 45
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 42
- 239000003431 cross linking reagent Substances 0.000 description 40
- 210000004379 membrane Anatomy 0.000 description 39
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- 239000004615 ingredient Substances 0.000 description 25
- 229920000974 Poly(dimethylsiloxane-ethylene oxide) Polymers 0.000 description 22
- 229910052697 platinum Inorganic materials 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- 239000002202 Polyethylene glycol Substances 0.000 description 20
- 229920001577 copolymer Polymers 0.000 description 18
- 238000004132 cross linking Methods 0.000 description 17
- 229920000578 graft copolymer Polymers 0.000 description 14
- 239000000377 silicon dioxide Substances 0.000 description 12
- 238000002156 mixing Methods 0.000 description 11
- 229920001400 block copolymer Polymers 0.000 description 10
- 229960000834 vinyl ether Drugs 0.000 description 8
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 229920002959 polymer blend Polymers 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- 238000004821 distillation Methods 0.000 description 6
- WRXCBRHBHGNNQA-UHFFFAOYSA-N (2,4-dichlorobenzoyl) 2,4-dichlorobenzenecarboperoxoate Chemical compound ClC1=CC(Cl)=CC=C1C(=O)OOC(=O)C1=CC=C(Cl)C=C1Cl WRXCBRHBHGNNQA-UHFFFAOYSA-N 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 230000009849 deactivation Effects 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000003760 magnetic stirring Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- FSIJKGMIQTVTNP-UHFFFAOYSA-N bis(ethenyl)-methyl-trimethylsilyloxysilane Chemical compound C[Si](C)(C)O[Si](C)(C=C)C=C FSIJKGMIQTVTNP-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000036647 reaction Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- VMAWODUEPLAHOE-UHFFFAOYSA-N 2,4,6,8-tetrakis(ethenyl)-2,4,6,8-tetramethyl-1,3,5,7,2,4,6,8-tetraoxatetrasilocane Chemical compound C=C[Si]1(C)O[Si](C)(C=C)O[Si](C)(C=C)O[Si](C)(C=C)O1 VMAWODUEPLAHOE-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000005331 crown glasses (windows) Substances 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940126703 systemic medication Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- VTUKXQJQUNIRSN-UHFFFAOYSA-N trioxasiletane Chemical compound O1O[SiH2]O1 VTUKXQJQUNIRSN-UHFFFAOYSA-N 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N vinyl-ethylene Natural products C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
- C08L83/10—Block- or graft-copolymers containing polysiloxane sequences
- C08L83/12—Block- or graft-copolymers containing polysiloxane sequences containing polyether sequences
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Silicon Polymers (AREA)
- Medicinal Preparation (AREA)
- Wrappers (AREA)
- Manufacture Of Macromolecular Shaped Articles (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Materials For Medical Uses (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI981506A FI107339B (fi) | 1998-06-30 | 1998-06-30 | Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200006986B true ZA200006986B (en) | 2001-05-23 |
Family
ID=8552104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200006986A ZA200006986B (en) | 1998-06-30 | 2000-11-28 | A membrane or matrix for controlling the permeation rate of drugs. |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1124902B1 (de) |
| JP (1) | JP2002519467A (de) |
| KR (1) | KR100599868B1 (de) |
| CN (2) | CN1176999C (de) |
| AR (1) | AR018952A1 (de) |
| AT (1) | ATE290049T1 (de) |
| AU (1) | AU752895B2 (de) |
| BG (1) | BG65148B1 (de) |
| BR (1) | BR9911140B1 (de) |
| CA (1) | CA2336149C (de) |
| CO (1) | CO5060523A1 (de) |
| CZ (1) | CZ299613B6 (de) |
| DE (1) | DE69923992T2 (de) |
| EE (1) | EE04685B1 (de) |
| ES (1) | ES2237120T3 (de) |
| FI (1) | FI107339B (de) |
| HK (1) | HK1038939A1 (de) |
| HU (1) | HU229159B1 (de) |
| NO (1) | NO327955B1 (de) |
| NZ (1) | NZ508275A (de) |
| PE (1) | PE20000935A1 (de) |
| PL (1) | PL193485B1 (de) |
| PT (1) | PT1124902E (de) |
| RU (1) | RU2201794C2 (de) |
| SK (1) | SK285325B6 (de) |
| TW (1) | TWI237571B (de) |
| UA (1) | UA71566C2 (de) |
| WO (1) | WO2000000550A1 (de) |
| ZA (1) | ZA200006986B (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6476079B1 (en) * | 1999-12-23 | 2002-11-05 | Leiras Oy | Devices for the delivery of drugs having antiprogestinic properties |
| AU2002210580A1 (en) * | 2000-10-20 | 2002-04-29 | Leiras Oy | Drug delivery system |
| EP1438942A1 (de) | 2003-01-17 | 2004-07-21 | Schering Oy | Medikamentenabgabevorrichtung für das Mittelohr und Nase |
| CN101006124B (zh) * | 2004-08-25 | 2010-11-24 | 联合碳化化学及塑料技术有限责任公司 | 聚合薄膜 |
| US7862552B2 (en) | 2005-05-09 | 2011-01-04 | Boston Scientific Scimed, Inc. | Medical devices for treating urological and uterine conditions |
| AU2008225731B2 (en) | 2007-03-12 | 2012-11-22 | Bayer Schering Pharma Oy | Use of tocopherol |
| EP2140860A1 (de) | 2008-07-03 | 2010-01-06 | Bayer Schering Pharma Oy | Verbessertes Verhütungsverfahren |
| FI20080523A0 (fi) | 2008-09-17 | 2008-09-17 | Bayer Schering Pharma Oy | Insertteri |
| FI20080524A0 (fi) | 2008-09-17 | 2008-09-17 | Bayer Schering Pharma Oy | Insertteri |
| US11992431B2 (en) | 2008-09-17 | 2024-05-28 | Bayer Oy | Inserter |
| CA2736020C (en) | 2008-09-17 | 2016-12-06 | Bayer Oy | An inserter |
| FI122579B (fi) | 2010-10-29 | 2012-03-30 | Bayer Oy | Insertteri |
| CN102008909B (zh) * | 2010-12-13 | 2012-10-10 | 大连欧科膜技术工程有限公司 | 一种气体分离复合膜的制备方法 |
| CN102068914B (zh) * | 2010-12-13 | 2012-10-10 | 大连欧科膜技术工程有限公司 | 一种气体分离复合膜的制备方法 |
| KR20150005548A (ko) | 2012-04-23 | 2015-01-14 | 바이엘 파마 악티엔게젤샤프트 | 월경과다증의 치료에서의 18-메틸-15β,16β-메틸렌-19-노르-20-스피록스-4-엔-3-온 시스템의 용도, 및 자궁 출혈 장애의 치료를 위한 18-메틸-15β,16β-메틸렌-19-노르-20-스피록스-4-엔-3-온을 함유하는 자궁내 시스템 |
| TW201350122A (zh) | 2012-04-23 | 2013-12-16 | Bayer Pharma AG | １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途 |
| PE20160534A1 (es) * | 2013-10-18 | 2016-06-15 | Bayer Oy | Sistema de administracion intrauterina |
| WO2016180764A1 (en) | 2015-05-13 | 2016-11-17 | Bayer Oy | A long acting drug delivery device and its use in contraception |
| WO2018202574A1 (en) | 2017-05-04 | 2018-11-08 | Bayer Oy | Intravaginal drug delivery system, method for manufacturing such system and its use in gynecological therapies and contraception |
| EP3536735B1 (de) * | 2018-03-05 | 2020-10-14 | Evonik Operations GmbH | Vernetzte polyether-siloxan block-copolymere sowie deren verwendung zur herstellung von polyurethanschaumstoffen |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5889108A (en) * | 1997-06-02 | 1999-03-30 | Dow Corning Corporation | Thickening solvents with elastomeric silicone polyethers |
-
1998
- 1998-06-30 FI FI981506A patent/FI107339B/fi not_active IP Right Cessation
-
1999
- 1999-06-04 TW TW088109291A patent/TWI237571B/zh not_active IP Right Cessation
- 1999-06-08 CO CO99035747A patent/CO5060523A1/es unknown
- 1999-06-11 EP EP99931285A patent/EP1124902B1/de not_active Expired - Lifetime
- 1999-06-11 KR KR1020007015121A patent/KR100599868B1/ko not_active IP Right Cessation
- 1999-06-11 JP JP2000557307A patent/JP2002519467A/ja active Pending
- 1999-06-11 CN CNB998081388A patent/CN1176999C/zh not_active Expired - Fee Related
- 1999-06-11 WO PCT/FI1999/000511 patent/WO2000000550A1/en active IP Right Grant
- 1999-06-11 PT PT99931285T patent/PT1124902E/pt unknown
- 1999-06-11 BR BRPI9911140-3A patent/BR9911140B1/pt not_active IP Right Cessation
- 1999-06-11 EE EEP200000788A patent/EE04685B1/xx not_active IP Right Cessation
- 1999-06-11 PL PL99345103A patent/PL193485B1/pl unknown
- 1999-06-11 CZ CZ20004749A patent/CZ299613B6/cs not_active IP Right Cessation
- 1999-06-11 CA CA002336149A patent/CA2336149C/en not_active Expired - Fee Related
- 1999-06-11 HU HU0102600A patent/HU229159B1/hu not_active IP Right Cessation
- 1999-06-11 ES ES99931285T patent/ES2237120T3/es not_active Expired - Lifetime
- 1999-06-11 SK SK1894-2000A patent/SK285325B6/sk not_active IP Right Cessation
- 1999-06-11 NZ NZ508275A patent/NZ508275A/xx not_active IP Right Cessation
- 1999-06-11 DE DE69923992T patent/DE69923992T2/de not_active Expired - Lifetime
- 1999-06-11 AT AT99931285T patent/ATE290049T1/de active
- 1999-06-11 AU AU47839/99A patent/AU752895B2/en not_active Ceased
- 1999-06-11 RU RU2001102606/04A patent/RU2201794C2/ru not_active IP Right Cessation
- 1999-06-11 CN CNB031429661A patent/CN1269909C/zh not_active Expired - Fee Related
- 1999-06-25 PE PE1999000584A patent/PE20000935A1/es not_active Application Discontinuation
- 1999-06-25 AR ARP990103082A patent/AR018952A1/es active IP Right Grant
- 1999-11-06 UA UA2001010652A patent/UA71566C2/uk unknown
-
2000
- 2000-11-28 ZA ZA200006986A patent/ZA200006986B/en unknown
- 2000-12-21 BG BG105081A patent/BG65148B1/bg unknown
- 2000-12-21 NO NO20006581A patent/NO327955B1/no not_active IP Right Cessation
-
2002
- 2002-01-21 HK HK02100469A patent/HK1038939A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200006986B (en) | A membrane or matrix for controlling the permeation rate of drugs. | |
| CZ291399B6 (cs) | Způsob pro řízení průniku léků po delší časový úsek | |
| EP3309220B1 (de) | Organopolysiloxanzusammensetzung und verfahren zur herstellung davon und silikonzusammensetzung für nebelsuppressor sowie trennpapier oder trennfolie ohne lösungsmittel | |
| EP2118174B1 (de) | Verwendung von tocopherol | |
| EP4214268A1 (de) | Funktionalisierte polymere materialien auf q-t-siloxan-basis mit niedrigem siloxanringgehalt, spezifischem polymerisationsgrad und verfahren zur herstellung davon | |
| JPS6147170B2 (de) | ||
| US6794464B2 (en) | Membrane or matrix for controlling the permeation rate of drugs | |
| US6887948B2 (en) | Method for preparing a siloxane-based elastomer composition | |
| JPH02232262A (ja) | 重付加反応により、架橋して粘着性と親水性と親油性のすべて或いはそのいずれかの特性を持つエラストマーになり得るオルガノポリシロキサン組成物 | |
| MXPA00012749A (en) | A membrane or matrix for controlling the permeation rate of drugs | |
| EP1970397A1 (de) | Hydrophile Polysiloxanelastomere |